Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may be influenced by germline variants in the enzymes r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacogenet Genomics
Päätekijät: Hertz, Daniel L., Douglas, Julie A., Kidwell, Kelley M., Gersch, Christina L., Desta, Zeruesenay, Storniolo, Ana-Maria, Stearns, Vered, Skaar, Todd C, Hayes, Daniel F, Henry, N. Lynn, Rae, James M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8185249/
https://ncbi.nlm.nih.gov/pubmed/34096894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000429
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia